Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | CCR8 | P51685 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | PRKCI | P41743 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4201172 | 0.81 | PDXK (0.33) | ALDH1A1AXLPRKCINOS3NOS2 | |
| SCHEMBL5303261 | 0.78 | ALDH1A1 (0.34) | DAOCCR1CCR5CCR8ALDH1A1 | |
| SCHEMBL2085241 | 0.78 | NOS2 (0.46) | CCR1CCR5CCR8ALDH1A1NOS3 | |
| SCHEMBL5212066 | 0.77 | ALDH1A1 (0.48) | DAOCCR1CCR5CCR8ALDH1A1 | |
| SCHEMBL31711446 | 0.75 | CCR1 (0.36) | DAOCCR1CCR5CCR8ALDH1A1 | |
| SCHEMBL20767182 | 0.75 | CCR1 (0.35) | CCR1CCR5CCR8ALDH1A1NOS3 | |
| SCHEMBL14691566 | 0.75 | NFE2L2 (0.35) | DAOCCR1CCR5CCR8ALDH1A1 | |
| SCHEMBL3719916 | 0.75 | TRIM24 (0.35) | DAOCCR1CCR5CCR8ALDH1A1 | |
| SCHEMBL29544937 | 0.75 | NFE2L2 (0.35) | DAOCCR1CCR5CCR8ALDH1A1 | |
| SCHEMBL28281345 | 0.75 | CCR1 (0.32) | CCR1CCR5CCR8ALDH1A1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705293-A1 | SPIRO-HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | Amgen Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4598916-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | Amgen Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| WO-2024229317-A1 | SPIRO-HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2024-11-07 | — | — | WO | disclosed |
| WO-2024076672-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20210363139-A1 | CXCR4 INHIBITORS AND USES THEREOF | X4 PHARMACEUTICALS, INC. | 2021-11-25 | — | — | US | disclosed |
| US-10988465-B2 | CXCR4 inhibitors and uses thereof | X4 PHARMACEUTICALS, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20200255414-A1 | CXCR4 INHIBITORS AND USES THEREOF | X4 PHARMACEUTICALS, INC. | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255414-A1 | CXCR4 INHIBITORS AND USES THEREOF | CXCR4, CXCL12, CXCR3 | DAO 4079/4885CCR1 15/4885CCR5 6/4885 |
| US-20210363139-A1 | CXCR4 INHIBITORS AND USES THEREOF | CXCR4, CXCL12, CXCR3 | DAO 4079/4885CCR1 15/4885CCR5 6/4885 |
| US-10988465-B2 | CXCR4 inhibitors and uses thereof | CXCR4, CXCL12, CXCR3 | DAO 4079/4885CCR1 15/4885CCR5 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.